Trinity Biotech PLC (TRIB) stock

TRIBNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 30, 2026Score 1/30

$6.10+0.22 (+3.74%)

Close on Nov 13, 2026Market cap $114.13MP/E –Yield –

Trinity Biotech EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Trinity Biotech's EV/EBITDA was 6.8× on Feb 28, 2023, against 374.9× a year earlier. Over the last 2 years it ranged from 6.3× to 812.1×, with a median of 374.9×.

EV/EBITDA at the end of each year

Period	Period end	Value	Change (pts)
2023	Feb 28, 2023	6.8×	+0.5
2022	Dec 30, 2022	6.3×	−368.6
2017	Feb 28, 2017	374.9×	−43.6
2016	Dec 30, 2016	418.4×	–

Where these numbers come from

Parsed from the XBRL in Trinity Biotech's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-30 reverse split on Jul 24, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing